Artigo Acesso aberto Revisado por pares

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials

2023; Oxford University Press; Volume: 230; Issue: 1 Linguagem: Inglês

10.1093/infdis/jiad580

ISSN

1537-6613

Autores

Emilie R Elliot, Joseph W. Polli, Parul Patel, Louise Garside, Richard Grove, Vincent A. Barnett, Jeremy Roberts, Sri Byrapuneni, Herta Crauwels, Susan L. Ford, Rodica Van Solingen‐Ristea, Eileen Birmingham, Ronald D’Amico, Bryan Baugh, Jean van Wyk,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

Cabotegravir + rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of HIV-1 virologic suppression. This post hoc analysis summarizes CAB + RPV LA results by baseline body mass index (BMI) category among Phase 3/3b trial participants.

Referência(s)